ABBV vs JAZZ
ABBV: A global biopharmaceutical leader focused on developing innovative, specialized therapies for immunology, oncology, neuroscience, and aesthetic medicine. JAZZ: Jazz Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative medicines for patients with complex sleep disorders and challenging oncology conditions.
Side-by-side fundamentals
| Metric | ABBV | JAZZ | Edge |
|---|---|---|---|
| Price as of 2026-08-05 close | $246.20 | $261.57 | |
| Market cap as of 2026-08-06 | $435.0B | $16.4B | |
| P/E as of 2026-08-06 | 118.52 | 570.94 | ABBV lower |
| PEG as of 2026-08-06 | 6.59 | 65.11 | ABBV lower |
| Net margin as of 2026-08-06 | +5.8% | +0.7% | ABBV higher |
| Gross margin as of 2026-08-06 | +72.0% | +88.0% | JAZZ higher |
| Operating margin as of 2026-08-06 | +24.4% | -0.8% | ABBV higher |
| ROE as of 2026-08-06 | +95.6% | +0.7% | ABBV higher |
| ROA as of 2026-08-06 | +2.7% | +0.3% | ABBV higher |
| Debt / equity as of 2026-08-06 | 49.22 | 1.18 | JAZZ lower |
| Revenue growth (YoY) as of 2026-08-06 | +9.5% | +9.2% | ABBV higher |
| Revenue CAGR (3y) SEC XBRL | +1.8% | +5.3% | JAZZ higher |
| Dividend yield as of 2026-08-06 | +2.8% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-06 | 0.21 | 0.37 | |
| 1-year return as of 2026-08-05 close | +24.0% | +131.1% | JAZZ higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-05.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.